Literature DB >> 8968895

Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi.

A Espinel-Ingroff1, M Bartlett, R Bowden, N X Chin, C Cooper, A Fothergill, M R McGinnis, P Menezes, S A Messer, P W Nelson, F C Odds, L Pasarell, J Peter, M A Pfaller, J H Rex, M G Rinaldi, G S Shankland, T J Walsh, I Weitzman.   

Abstract

A multicenter study was conducted to expand the generation and analysis of data that supports the proposal of a reference method for the antifungal susceptibility testing of filamentous fungi. Broth microdilution MICs of amphotericin B and itraconazole were determined in 11 centers against 30 coded duplicate pairs of Aspergillus spp., Fusarium spp., Pseudallescheria boydii, and Rhizopus arrhizus. The effect of inoculum density (approximately 10(3) and 10(4) CFU/ml), incubation time (24, 48, and 72 h), and procedure of MIC determination (conventional and colorimetric [Alamar Blue] evaluation of growth inhibition) on intra- and interlaboratory agreement was analyzed. Based on intra- (97 to 100%) and interlaboratory (94 to 95%) agreement for both drugs, the overall optimal testing conditions identified were determination of colorimetric MICs after 48 to 72 h of incubation with an inoculum density of approximately 10(4) CFU/ml. These testing conditions are proposed as guidelines for a reference broth microdilution method.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 8968895      PMCID： PMC229526          DOI： 10.1128/jcm.35.1.139-143.1997

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  16 in total

1.  Lack of activity of amphotericin B in systemic murine fusarial infection.

Authors:  E J Anaissie; R Hachem; C Legrand; P Legenne; P Nelson; G P Bodey
Journal:  J Infect Dis       Date:  1992-06       Impact factor: 5.226

2.  Quality control guidelines for National Committee for Clinical Laboratory Standards--recommended broth macrodilution testing of ketoconazole and itraconazole.

Authors:  J H Rex; M A Pfaller; M Lancaster; F C Odds; A Bolmström; M G Rinaldi
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

3.  Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System.

Authors:  C Beck-Sagué; W R Jarvis
Journal:  J Infect Dis       Date:  1993-05       Impact factor: 5.226

Review 4.  Emerging fungal pathogens in immunocompromised patients: classification, diagnosis, and management.

Authors:  S E Vartivarian; E J Anaissie; G P Bodey
Journal:  Clin Infect Dis       Date:  1993-11       Impact factor: 9.079

5.  Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts.

Authors:  R A Fromtling; J N Galgiani; M A Pfaller; A Espinel-Ingroff; K F Bartizal; M S Bartlett; B A Body; C Frey; G Hall; G D Roberts
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

6.  NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis.

Authors:  D W Denning; J Y Lee; J S Hostetler; P Pappas; C A Kauffman; D H Dewsnup; J N Galgiani; J R Graybill; A M Sugar; A Catanzaro
Journal:  Am J Med       Date:  1994-08       Impact factor: 4.965

7.  Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi.

Authors:  A Espinel-Ingroff; K Dawson; M Pfaller; E Anaissie; B Breslin; D Dixon; A Fothergill; V Paetznick; J Peter; M Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

Review 8.  Importance of Candida species other than C. albicans as pathogens in oncology patients.

Authors:  J R Wingard
Journal:  Clin Infect Dis       Date:  1995-01       Impact factor: 9.079

9.  Response to antifungal therapy by human immunodeficiency virus-infected patients with disseminated Penicillium marneffei infections and in vitro susceptibilities of isolates from clinical specimens.

Authors:  K Supparatpinyo; K E Nelson; W G Merz; B J Breslin; C R Cooper; C Kamwan; T Sirisanthana
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

10.  Improved medium for fluconazole susceptibility testing of Candida albicans.

Authors:  J L Rodriguez-Tudela; J V Martinez-Suarez
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191
View more
  81 in total

1.  Inoculum standardization for antifungal susceptibility testing of filamentous fungi pathogenic for humans.

Authors:  E Petrikkou; J L Rodríguez-Tudela; M Cuenca-Estrella; A Gómez; A Molleja; E Mellado
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

2.  Comparison of three methods of determining MICs for filamentous fungi using different end point criteria and incubation periods.

Authors:  C Llop; I Pujol; C Aguilar; J Sala; D Riba; J Guarro
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

3.  In vitro activity of Syn-2869, a novel triazole agent, against emerging and less common mold pathogens.

Authors:  E M Johnson; A Szekely; D W Warnock
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

Review 4.  Antifungal susceptibility testing: practical aspects and current challenges.

Authors:  J H Rex; M A Pfaller; T J Walsh; V Chaturvedi; A Espinel-Ingroff; M A Ghannoum; L L Gosey; F C Odds; M G Rinaldi; D J Sheehan; D W Warnock
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

5.  Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp.: NCCLS collaborative evaluation. National Committee for Clinical Laboratory Standards.

Authors:  A Espinel-Ingroff; M Bartlett; V Chaturvedi; M Ghannoum; K C Hazen; M A Pfaller; M Rinaldi; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

6.  Fluorometric assessment of In vitro antidermatophytic activities of antimycotics based on their keratin-penetrating power.

Authors:  C N Okeke; R Tsuboi; M Kawai; H Ogawa
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

7.  Preliminary evaluation of a semisolid agar antifungal susceptibility test for yeasts and molds.

Authors:  H Provine; S Hadley
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

8.  Use of the sensititre colorimetric microdilution panel for antifungal susceptibility testing of dermatophytes.

Authors:  I Pujol; J Capilla; B Fernández-Torres; M Ortoneda; J Guarro
Journal:  J Clin Microbiol       Date:  2002-07       Impact factor: 5.948

9.  Nationwide survey of in vitro activities of itraconazole and voriconazole against clinical Aspergillus fumigatus isolates cultured between 1945 and 1998.

Authors:  Paul E Verweij; Debbie T A Te Dorsthorst; Anthonius J M M Rijs; Hilly G De Vries-Hospers; Jacques F G M Meis
Journal:  J Clin Microbiol       Date:  2002-07       Impact factor: 5.948

10.  Intra- and interlaboratory study of a method for testing the antifungal susceptibilities of dermatophytes.

Authors:  M A Ghannoum; V Chaturvedi; A Espinel-Ingroff; M A Pfaller; M G Rinaldi; W Lee-Yang; D W Warnock
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.